Unified Patent Court (UPC) analytics are now available. Check here

EP2504353

CUBIST PHARMACEUTICALS
Application Number
EP10832379A
Filing Date
Nov 23, 2010
Status
Patent Maintained As Amended
Aug 11, 2023
Grant Date
Sep 13, 2023
External Links
Slate, Register, Google Patents

Biblio Summary

The patent EP2504353B2 was granted on Sep 13, 2023 by Cubist Pharmaceuticals The patent is currently Patent Maintained As Amended.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

PAJAROApr 11, 2019ADMISSIBLE
HGFApr 10, 2019ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionEP2504353B2
N/A
OppositionUS2006029599
N/A
OppositionEP0386951
N/A
OppositionWO2008012310
N/A
OppositionUS5952300
N/A
OppositionWO0153330
N/A
OppositionUS2005027113
N/A
OppositionWO2007061529
N/A
OppositionWO2009002481
N/A
OppositionWO2011063419
N/A
OppositionWO2011062676
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.